Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Randomised, Single Centre Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three or Four Doses of Meningococcal Serogroup B Outer Membrane Vesicle (OMV) Vaccine MENZBTM When Administered to Healthy Adults (University Students)

NCT00443157 is registered in ClinicalTrials.gov with Public Health England as lead sponsor.

NCT NCT00443157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00443157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Randomised, Single Centre Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Three or Four Doses of Meningococcal Serogroup B Outer Membrane Vesicle (OMV) Vaccine MENZBTM When Administered to Healthy Adults (University Students)
Lead sponsor
Public Health England
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
March 31, 2007
Enrollment
50
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neisseria meningitidis serogroup b